Pasithea Therapeutics (KTTA) EBT (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed EBT for 4 consecutive years, with -$3.2 million as the latest value for Q4 2024.
- Quarterly EBT rose 36.84% to -$3.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$13.9 million through Dec 2024, up 10.34% year-over-year, with the annual reading at -$20.4 million for FY2025, 46.91% down from the prior year.
- EBT hit -$3.2 million in Q4 2024 for Pasithea Therapeutics, down from -$3.0 million in the prior quarter.
- In the past five years, EBT ranged from a high of $630143.0 in Q4 2021 to a low of -$5.0 million in Q4 2023.
- Historically, EBT has averaged -$2.7 million across 4 years, with a median of -$3.2 million in 2023.
- Biggest five-year swings in EBT: tumbled 743.25% in 2022 and later skyrocketed 36.84% in 2024.
- Year by year, EBT stood at $630143.0 in 2021, then tumbled by 743.25% to -$4.1 million in 2022, then decreased by 24.12% to -$5.0 million in 2023, then surged by 36.84% to -$3.2 million in 2024.
- Business Quant data shows EBT for KTTA at -$3.2 million in Q4 2024, -$3.0 million in Q3 2024, and -$3.9 million in Q2 2024.